133 related articles for article (PubMed ID: 23200539)
1. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Garcia-Manero G
Best Pract Res Clin Haematol; 2012 Dec; 25(4):427-35. PubMed ID: 23200539
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic image (92). A man with fever during chemotherapy. Invasive pulmonary mycosis].
van Spronsen DJ; Daenen SM; Kluin-Nelemans JC
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1126. PubMed ID: 12092303
[TBL] [Abstract][Full Text] [Related]
5. Is obesity a prognostic factor for acute myeloid leukemia outcome?
Lee HJ; Licht AS; Hyland AJ; Ford LA; Sait SN; Block AW; Barcos M; Baer MR; Wang ES; Wetzler M
Ann Hematol; 2012 Mar; 91(3):359-65. PubMed ID: 21935651
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Appelbaum FR
Nat Rev Clin Oncol; 2010 Nov; 7(11):619-21. PubMed ID: 20981126
[No Abstract] [Full Text] [Related]
8. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Garcia-Manero G; Tambaro FP; Bekele NB; Yang H; Ravandi F; Jabbour E; Borthakur G; Kadia TM; Konopleva MY; Faderl S; Cortes JE; Brandt M; Hu Y; McCue D; Newsome WM; Pierce SR; de Lima M; Kantarjian HM
J Clin Oncol; 2012 Jun; 30(18):2204-10. PubMed ID: 22585696
[TBL] [Abstract][Full Text] [Related]
9. Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin.
Jogi R; Garman M; Pielop J; Orengo I; Hsu S
J Drugs Dermatol; 2005; 4(5):652-6. PubMed ID: 16167426
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Warlick ED; Cao Q; Miller J
Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
[No Abstract] [Full Text] [Related]
11. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Erba HP; Sayar H; Juckett M; Lahn M; Andre V; Callies S; Schmidt S; Kadam S; Brandt JT; Van Bockstaele D; Andreeff M
Invest New Drugs; 2013 Aug; 31(4):1023-34. PubMed ID: 23397500
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Kadia TM; Yang H; Ferrajoli A; Maddipotti S; Schroeder C; Madden TL; Holleran JL; Egorin MJ; Ravandi F; Thomas DA; Newsome W; Sanchez-Gonzalez B; Zwiebel JA; Espinoza-Delgado I; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2010 Jul; 150(1):72-82. PubMed ID: 20456355
[TBL] [Abstract][Full Text] [Related]
14. Acute basophilic leukemia.
Eveillard M; Desjonqueres A
Blood; 2014 May; 123(20):3071. PubMed ID: 24949509
[No Abstract] [Full Text] [Related]
15. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani AS; Li H; Michaelis LC; Medeiros BC; Liedtke M; List AF; O'Dwyer K; Othus M; Erba HP; Appelbaum FR
Leuk Res; 2018 Apr; 67():17-20. PubMed ID: 29407182
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
17. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
18. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-induced bradycardia in a patient with refractory leukemia.
Chung-Lo W; Hsieh CY; Chiu CF; Bai LY
Ann Saudi Med; 2010; 30(3):246-7. PubMed ID: 20427948
[No Abstract] [Full Text] [Related]
20. Miliaria-rash after neutropenic fever and induction chemotherapy for acute myelogenous leukemia.
Nguyen TA; Ortega-Loayza AG; Stevens MP
An Bras Dermatol; 2011; 86(4 Suppl 1):S104-6. PubMed ID: 22068785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
